Stoke Therapeutics
Stoke Therapeutics Inc is an American clinical-stage biotechnology company developing RNA-targeted antisense oligonucleotide medicines to treat severe genetic diseases. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output platform to restore protein levels by upregulating gene expression, with lead candidate zorevunersen targeting Dravet syndrome. Main revenue drivers currently comprise investment capital, research grants, and potential biopharmaceutical milestone payments as clinical pipeline development advances. Stoke Therapeutics targets pediatric neurologists, clinical trial networks, specialized research centers, and patients suffering from rare genetic neurodegenerative conditions across North America and Europe. The company holds an innovative position in precision RNA therapeutics and genetic upregulation medicine. Headquartered in Bedford, Massachusetts, Stoke Therapeutics Inc is listed on the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in Stoke Therapeutics.
- Legal name
- STOKE THERAPEUTICS
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
- Exposure themes
- Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics
Funds holding Stoke Therapeutics
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.16 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.11 % (full portfolio disclosed, October 2026)
- Mercer Global Small Cap Equity Fund — Mercer · 0.06 % (full portfolio disclosed, December 2025)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)